Literature DB >> 2982913

Glucagon receptor of human liver. Studies of its molecular weight and binding properties, and its ability to activate hepatic adenylyl cyclase of non-obese and obese subjects.

J N Livingston, K Einarsson, L Backman, S Ewerth, P Arner.   

Abstract

The glucagon receptor and the adenylyl cyclase system of human liver membranes were studied in six non-obese and six obese subjects who had elevated insulin and plasma glucagon levels. Analysis of specific glucagon binding by the method of Scatchard demonstrated a linear (monocomponent) plot with a dissociation constant of 2-3 nM, and the binding at low hormone concentrations was sensitive to guanosine triphosphate (GTP). The molecular weight of the glucagon receptor was 63,000 D as determined by an affinity labeling procedure and sodium dodecyl sulfate gel electrophoresis. Affinity labeling of this structure was specific for glucagon and inhibited by GTP. Glucagon stimulated the production of cyclic adenosine monophosphate (cAMP) by human membranes with half-maximal activation elicited by 6 nM hormone. The human cyclase system required GTP to facilitate an optimal glucagon response. NaF (10 mM) also activated the cyclase system and produced the same magnitude of response as maximum glucagon activation. A comparison of the liver adenylyl cyclase system of non-obese and obese subjects was made using glucagon (5 nM and 1 microM) and NaF (10 mM). No significant differences in cAMP production were noted between the two groups, regardless of the agent used to activate the enzyme. These findings agree with the glucagon binding studies that showed similar amounts of binding activity in the membranes from the two groups. Also, there was no influence of either age or sex of the subjects on the adenylyl cyclase response. In conclusion, human liver membranes contain a glucagon receptor and an adenylyl cyclase system that correspond closely to the well-studied system in animal liver. This system in human obesity is not altered by the approximately twofold elevation in plasma glucagon that occurs in this metabolic disorder.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2982913      PMCID: PMC423504          DOI: 10.1172/JCI111713

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  30 in total

1.  Role of phosphodiesterase in glucagon resistance of large adipocytes.

Authors:  R A De Santis; T Gorenstein; J N Livingston; D H Lockwood
Journal:  J Lipid Res       Date:  1974-01       Impact factor: 5.922

2.  A rapid method for the isolation of rat liver plasma membranes using an aqueous two-phase polymer system.

Authors:  L Lesko; M Donlon; G V Marinetti; J D Hare
Journal:  Biochim Biophys Acta       Date:  1973-06-22

3.  Insulin and glucagon degradation by the same enzyme.

Authors:  W C Duckworth; A E Kitabchi
Journal:  Diabetes       Date:  1974-06       Impact factor: 9.461

4.  A highly sensitive adenylate cyclase assay.

Authors:  Y Salomon; C Londos; M Rodbell
Journal:  Anal Biochem       Date:  1974-04       Impact factor: 3.365

5.  The glucagon-sensitive adenyl cyclase system in plasma membranes of rat liver. V. An obligatory role of guanylnucleotides in glucagon action.

Authors:  M Rodbell; L Birnbaumer; S L Pohl; H M Krans
Journal:  J Biol Chem       Date:  1971-03-25       Impact factor: 5.157

6.  Radioimmunological determination of pancreatic and gut glucagon in plasma.

Authors:  L G Heding
Journal:  Diabetologia       Date:  1971-02       Impact factor: 10.122

7.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

8.  Structural analysis of the hepatic glucagon receptor. Identification of a guanine nucleotide-sensitive hormone-binding region.

Authors:  R Iyengar; J T Herberg
Journal:  J Biol Chem       Date:  1984-04-25       Impact factor: 5.157

9.  Studies of glucagon resistance in large rat adipocytes: 125I-labeled glucagon binding and lipolytic capacity.

Authors:  J N Livingston; P Cuatrecasas; D H Lockwood
Journal:  J Lipid Res       Date:  1974-01       Impact factor: 5.922

10.  Kinetics of glucagon in man: effects of starvation.

Authors:  M Fisher; R S Sherwin; R Hendler; P Felig
Journal:  Proc Natl Acad Sci U S A       Date:  1976-05       Impact factor: 11.205

View more
  4 in total

1.  Altered action of glucagon on human liver in type 2 (non-insulin-dependent) diabetes mellitus.

Authors:  P Arner; K Einarsson; S Ewerth; J N Livingston
Journal:  Diabetologia       Date:  1987-05       Impact factor: 10.122

Review 2.  Glucagon, cyclic AMP, and hepatic glucose mobilization: A half-century of uncertainty.

Authors:  Robert L Rodgers
Journal:  Physiol Rep       Date:  2022-05

3.  Insulin-like stimulation of cardiac fuel metabolism by physiological levels of glucagon: involvement of PI3K but not cAMP.

Authors:  Julie A Harney; Robert L Rodgers
Journal:  Am J Physiol Endocrinol Metab       Date:  2008-05-20       Impact factor: 4.310

4.  Glucagon's Metabolic Action in Health and Disease.

Authors:  Anja Zeigerer; Revathi Sekar; Maximilian Kleinert; Shelly Nason; Kirk M Habegger; Timo D Müller
Journal:  Compr Physiol       Date:  2021-04-01       Impact factor: 9.090

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.